1. Home
  2. CAN vs BMEA Comparison

CAN vs BMEA Comparison

Compare CAN & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CAN

Canaan Inc.

HOLD

Current Price

$0.41

Market Cap

486.0M

Sector

Technology

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.52

Market Cap

107.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAN
BMEA
Founded
2013
2017
Country
Singapore
United States
Employees
N/A
41
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
486.0M
107.7M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
CAN
BMEA
Price
$0.41
$1.52
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
7
Target Price
$3.21
$8.86
AVG Volume (30 Days)
9.1M
1.3M
Earning Date
05-19-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.19
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$63.64
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$0.87
52 Week High
$2.22
$3.07

Technical Indicators

Market Signals
Indicator
CAN
BMEA
Relative Strength Index (RSI) 39.76 62.69
Support Level N/A $1.22
Resistance Level $0.55 $1.66
Average True Range (ATR) 0.03 0.13
MACD 0.00 0.03
Stochastic Oscillator 22.65 86.54

Price Performance

Historical Comparison
CAN
BMEA

About CAN Canaan Inc.

Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: